Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $53.5 million.

  • Puma Biotechnology's Cash & Equivalents fell 2042.43% to $53.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.5 million, marking a year-over-year decrease of 2042.43%. This contributed to the annual value of $69.2 million for FY2024, which is 1816.63% down from last year.
  • Per Puma Biotechnology's latest filing, its Cash & Equivalents stood at $53.5 million for Q3 2025, which was down 2042.43% from $54.7 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Cash & Equivalents peaked at $95.7 million during Q1 2021, and registered a low of $52.8 million during Q2 2022.
  • For the 5-year period, Puma Biotechnology's Cash & Equivalents averaged around $69.6 million, with its median value being $67.1 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 4128.31% in 2022, then soared by 2501.38% in 2024.
  • Over the past 5 years, Puma Biotechnology's Cash & Equivalents (Quarter) stood at $63.1 million in 2021, then grew by 20.7% to $76.2 million in 2022, then rose by 11.0% to $84.6 million in 2023, then decreased by 18.17% to $69.2 million in 2024, then dropped by 22.67% to $53.5 million in 2025.
  • Its last three reported values are $53.5 million in Q3 2025, $54.7 million for Q2 2025, and $63.0 million during Q1 2025.